464920-03-4

Upstream product

• 346433-57-6 carbonic acid tert-butyl ester 3-hydroxy-4-(3-methyl-but-2-enyl)-phenyl ester 
• 288268-46-2 1-(hydroxy-methyl)-2,5-di-tert-butoxycarbonyloxy-benzene 
• 288268-32-6 bis-(2,4-tert-butoxycarbonyloxy)-benzaldehyde 
• 95-01-2 2,4-Dihydroxybenzaldehyde 

Downstream Products

• 1310328-61-0 2-{6-[3-(tert-butyldimethylsilanyloxy)phenyl]-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl}-propan-2-ol 
• 1310328-62-1 2-{6-[4-(tert-butyldimethylsilanyloxy)phenyl]-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl}-propan-2-ol 
• 1310328-29-0 2-[6-(3,5-dimethoxyphenyl)-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]propan-2-ol 
• 1310328-30-3 3-[6-(1-hydroxy-1-methylethyl)-5,6-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]phenol 
• 1310328-31-4 4-[6-(1-hydroxy-1-methylethyl)-5,6-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]phenol 
• 1310328-32-5 {4-[6-(1-hydroxy-1-methylethyl)-5,6-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]phenoxy}acetic acid ethyl ester 
• 1310328-33-6 2-[6-(4-benzyloxyphenyl)-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]propan-2-ol 
• 1310328-34-7 2-[6-(2-methoxyphenyl)-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]propan-2-ol 
• 1310328-35-8 2-[6-(3-methoxyphenyl)-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]propan-2-ol 
• 1310328-36-9 2-[6-(4-methoxyphenyl)-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl]propan-2-ol 
• 1310328-37-0 2-(6-phenyl-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl)propan-2-ol 
• 1310328-38-1 2-(6-p-tolyl-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl)propan-2-ol 
• 1310328-39-2 2-(6-(3,5-difluorophenyl)-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl)propan-2-ol 
• 1310328-42-7 3,5-dihydroxybenzoic acid 2-(1-hydroxy-1-methylethyl)-2,3-dihydrobenzofuran-6-yl ester 

Relevant academic research and scientific papers

HIF-1α inhibitors: Synthesis and biological evaluation of novel moracin O and P analogues

The natural products moracins O and P exhibited potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia. Systematic variations of the structures of benzofuran type moracins were made and structure-activity relationship analysis showed the importance of the 2-arylbenzofuran ring and the (R)-configuration of the core scaffold. Further evaluation of the representative compound 5 showed its inhibitory effect on HIF-1α protein accumulation and target gene expression under hypoxia.

Synthesis of the F11334's from o-prenylated phenols: ΜM inhibitors of neutral sphingomyelinase (N-SMase)

F11334A1, F11334A2, F11334A3, and their corresponding resorcinol analogs were synthesized along with F11334B1, and F11263. In the course of these synthetic studies, several conditions for manipulating (2,3-propanediol) and (2,3-epoxypropyl) o-substituted phenols were developed as well as a variety of conditions for cleavage of aryl O-t-butyl carbonates. From enzyme assays it appears that the hydroquinone nucleus is the essential structural necessary for N-SMase inhibition. Furthermore, it appears that this family of compounds is comprised of irreversible inhibitors.